Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 24, 2024
Daily News
January 24, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
- Around 70 APIs Right Now Are Good Candidates for Rx-to-OTC Switches: JSMI Chair
January 24, 2024
- Astellas to Discontinue IBS Med Colonel in Product Consolidation
January 24, 2024
- Astellas to Transfer Distribution Rights for Antibacterial Geninax to Taisho
January 24, 2024
- Cases of Xocova Use in Pregnant Women Now Total 34: MHLW
January 24, 2024
- Mitsubishi Tanabe, Pfizer to Copromote 5-in-1 Vaccine Gobik
January 24, 2024
- As Japan Sees Uptick in COVID Cases, Minister Says to Watch Situations
January 24, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…